| Ytd | 232.25% | |
| 1y | 1016.81% |
| Open | 12.89 | Prev Close | 13.04 | Low | 12.34 | High | 13.59 | Mkt Cap | 761.03M |
| Vol | 1.91M | Avg Vol | 1.10M | EPS | -0.77 | P/E | N/A | Forward P/E | N/A |
| Beta | -0.34 | Short Ratio | 15.74 | Inst. Own | 84.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 11.00 | 200-d Avg | 5.92 | 1yr Est | 10.00 |
CLYM News
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy
Up to $100,000,000Common StockWe have entered into an Open Market Sale AgreementSM, or the Sales Ag
Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletio
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price ta
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for pa
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive tr
Guggenheim analyst Yatin Suneja initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating a
The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotl